SCHEMBL19122095

SCHEMBL19122095

CC(C)c1ccc(Cl)c(O[C@@H](C)C(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.38
▸ GRIN1 Q05586 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ BCHE P06276 3/20 0.36
▸ ACHE P22303 3/20 0.36
▸ LMNA P02545 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ AKR1C3 P42330 1/20 0.33
▸ AKR1C2 P52895 1/20 0.33
▸ TRPA1 O75762 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ CACNA1C Q13936 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NPBWR1 P48145 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HIF1A Q16665 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13715960 0.85 CSNK2A1 (0.43) LMNANOS2AKR1C3AKR1C2TRPA1
SCHEMBL14827558 0.81 GRIN2B (0.45) RXRAGRIN1GRIN2B
SCHEMBL1104690 0.79 ALDH1A1 (0.47) AKR1C3AKR1C2SMN1; SMN2MAPTTSHR
SCHEMBL19121480 0.77 AKR1C3 (0.37) RXRAGRIN1GRIN2BBCHEACHE
SCHEMBL532778 0.76 LMNA (0.36) BCHEACHELMNAAKR1C3AKR1C2
SCHEMBL19120979 0.76 ACHE (0.36) BCHEACHELMNAAKR1C3AKR1C2
SCHEMBL19120778 0.75 CYP2C19 (0.39) RXRAGRIN1GRIN2BLMNASMN1; SMN2
SCHEMBL14039594 0.74 TP53 (0.46) BCHEACHELMNASMN1; SMN2MAPT
SCHEMBL17658863 0.73 ALDH1A1 (0.42) BCHEACHELMNASMN1; SMN2MAPT
SCHEMBL12810146 0.73 ALDH1A1 (0.41) NPBWR1MCHR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170196862-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196862-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 RXRA 931/4885GRIN1 2934/4885GRIN2B 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback